Ueda, A.; Umetsu, M.; Nakanishi, T.; Hashikami, K.; Nakazawa, H.; Hattori, S.; Asano, R.; Kumagai, I.
Chemically Crosslinked Bispecific Antibodies for Cancer Therapy: Breaking from the Structural Restrictions of the Genetic Fusion Approach. Int. J. Mol. Sci. 2020, 21, 711.
https://doi.org/10.3390/ijms21030711
AMA Style
Ueda A, Umetsu M, Nakanishi T, Hashikami K, Nakazawa H, Hattori S, Asano R, Kumagai I.
Chemically Crosslinked Bispecific Antibodies for Cancer Therapy: Breaking from the Structural Restrictions of the Genetic Fusion Approach. International Journal of Molecular Sciences. 2020; 21(3):711.
https://doi.org/10.3390/ijms21030711
Chicago/Turabian Style
Ueda, Asami, Mitsuo Umetsu, Takeshi Nakanishi, Kentaro Hashikami, Hikaru Nakazawa, Shuhei Hattori, Ryutaro Asano, and Izumi Kumagai.
2020. "Chemically Crosslinked Bispecific Antibodies for Cancer Therapy: Breaking from the Structural Restrictions of the Genetic Fusion Approach" International Journal of Molecular Sciences 21, no. 3: 711.
https://doi.org/10.3390/ijms21030711
APA Style
Ueda, A., Umetsu, M., Nakanishi, T., Hashikami, K., Nakazawa, H., Hattori, S., Asano, R., & Kumagai, I.
(2020). Chemically Crosslinked Bispecific Antibodies for Cancer Therapy: Breaking from the Structural Restrictions of the Genetic Fusion Approach. International Journal of Molecular Sciences, 21(3), 711.
https://doi.org/10.3390/ijms21030711